Cbcsg-10: Adjuvant Capecitabine In Combination With Docetaxel And Cyclophosphamide Plus Epirubicin For Triple Negative Breast Cancer.

1012Background: Standard adjuvant chemotherapy regimens for triple-negative breast cancer (TNBC) contain taxane and anthracycline. We aimed to investigate the efficacy and safety of integrate capecitabine in the adjuvant treatment of triple-negative patients. Methods: For this randomized, open-label, phase 3 trial undertaken at 35 institutions or hospitals in China, we recruited women with early TNBC after surgery. Eligible patients were randomly assigned (1:1) using a central patient screening and randomization system to either three cycles of capecitabine and docetaxel (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (XEC), or to three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (FEC). The primary endpoint was disease-free survival (DFS). This trial is registered with ClinicalTrials.gov, number NCT01642771. Results: Between Jun, 2012, and Nov, 2013, 585 patients were assessed for eligibility and randomized. 288 patient...